New drug shows promise for dangerous virus in blood cancer patients
NCT ID NCT07014319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug maribavir can safely control cytomegalovirus (CMV) infections in people with multiple myeloma or lymphoma who are receiving bispecific antibody therapy. About 20 adults will take maribavir, and researchers will measure how well it lowers CMV levels in the blood and track any side effects. The goal is to manage the virus without stopping cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?